Da. Liem et al., Role of adenosine in ischemic preconditioning in rats depends critically on the duration of the stimulus and involves both A(1) and A(3) receptors, CARDIO RES, 51(4), 2001, pp. 701-708
Citations number
18
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Objectives: There is currently general agreement that adenosine is not invo
lved in ischemic preconditioning (IP) in rat hearts. We hypothesized that t
he failure to show a role for adenosine is due to the use of brief precondi
tioning stimuli, and therefore investigated whether adenosine is involved w
hen longer stimuli are employed and which receptor subtypes are involved. M
ethods and results: Infarct size (IS) was determined in anesthetized rats a
fter 180 min of reperfusion (REP) following a 60-min coronary artery occlus
ion (CAO). IS was 69 +/-2% (n=15) of the risk area in control rats and 45 /-2% (n=19; P <0.05) following IP by a single 15-min CAO. The non-selective
adenosine receptor antagonist SPT, which itself had no effect on IS (74 +/
-1%), blunted the protection by IP (IS=57 +/-2%, P <0.05) in a dose of 2x5
mg/kg i.v., and abolished the protection (IS=70 +/-1%) at 2x25 mg/kg i.v. F
ollowing IP by three cycles of 3-min CAO and 3-min REP, IS was 24 +/-6% (P
<0.05), which was not affected by SPT in doses of 2x10 and 2x25 mg/kg i.v.
The A(3) antagonist MRS-1191 (3.3 mg/kg, i.p.), which itself did not affect
IS (70 +/-2%), blunted the protection by IP with a 15-min CAO (IS=54 +/-2%
, P <0.05). When 2x5 mg/kg SPT (a dose selective for A(1)-receptors, as it
did not affect the protection by the A(3) selective agonist IB-MECA, 51 +/-
3%) and MRS 1191 were combined the protection by IP was abolished (IS=67 +/
-2%). Conclusions: Involvement of adenosine in IP in rats depends criticall
y on the duration of the stimulus. Thus, whereas adenosine was not involved
when stimuli of 3-min duration were employed, activation of both A(1) and
A(3) receptors contributed when a stimulus of 15 min was used. (C) 2001 Els
evier Science B.V. All rights reserved.